NTRK2 and depressive disorder: These findings suggest that behavioral abnormalities (depression and behavioral sensitization) in mice after METH withdrawal were improved by subsequent repeated administration of the TrkB antagonist ANA-12, but not TrkB agonist 7,8-DHF.